Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy Induced Painful Peripheral Neuropathy: A Randomized Clinical Trial

• Autores: Ellen M Lavoie Smith, Herbert Pang, Constance Cirrincione, Stewart Fleishman, Electra D. Paskett
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 309, Nº. 13, 2013, págs. 1359-1367
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Design, Setting, and Patients Randomized, double-blind, placebo-controlled crossover trial at 8 National Cancer Institute (NCI)-funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.